Clinical Trial Update: SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for SHR-1701 as consolidation therapy after chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SHR-1701

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: NSCLC, Stage III | Phase 2 | Status: UNKNOWN